Keyphrases
Precision Medicine
97%
GLP-1 Receptor Agonist
85%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
85%
Diabetes
80%
Type 2 Diabetes Mellitus (T2DM)
70%
Clinical Features
65%
Type 2 Diabetes Prevention
42%
Heterogeneous Treatment Effects
42%
Clinical Translation
42%
Second International
42%
Glucagon-like
42%
Inhibitor-1
42%
Drug Treatment
42%
Targeted Treatment
42%
International Consensus
42%
Consensus Document
42%
A1 Receptor
42%
Precision Diabetes
42%
Drug Response
42%
Receptor Agonist
42%
Glycemic Response
28%
Glycemic Outcomes
22%
Clinical Genomics
21%
Prescription Drugs
21%
Clinical Markers
21%
Type 2 Diabetic Patients
21%
Potential Treatments
21%
Randomized Trial
21%
Disease Progression
21%
Clinical Manifestations
21%
Glycemic Targets
21%
Genomic Markers
21%
Genomic Features
21%
Adverse Outcomes
21%
Genetic Markers
21%
Adverse Effects
21%
Molecular Genetics
21%
Individual-based
21%
Recent Advances
21%
Clinical Trials
21%
Predictive Marker
21%
Real-world Trials
21%
Molecular Features
21%
Clinical Implementation
21%
Specific Group
21%
Trial Data
21%
Tailored Treatment
21%
Disease Heterogeneity
21%
Average Effect
21%
Agonist Treatment
17%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Diabetes
90%
Personalized Medicine
89%
Sodium Glucose Cotransporter 2 Inhibitor
85%
Glycemic
61%
Treatment Effect
52%
Receptor
42%
Systematic Review
42%
Medicine
42%
Drug Therapy
42%
Targeted Therapy
42%
Glucagon-Like Peptide-1 Agonist
42%
Drug Response
28%
Cotransporter
23%
Clinical Feature
23%
Clinical Trial
23%
Body Mass Index
14%
Predictive Marker
14%
Disease Exacerbation
14%
Disease
14%
Adverse Outcome
14%
Adverse Event
14%
Patient with Type 2 Diabetes
14%
Genetic Marker
14%
Observational Study
12%
Cardiovascular System
12%
Randomized Controlled Trial
12%
Meta-Analysis
12%
Liraglutide
9%
Microvascular Complication
9%
Evidence-Based Medicine
6%
Kidney Function
6%
Post-Hoc Analysis
6%
Cost-Effectiveness Analysis
6%
Combination Therapy
6%
Insulin Release
6%
Medical Decision Making
6%